Baxter receives European approval for HyQvia

Baxter has announced that its new therapy for primary and secondary immunodeficiencies HyQvia has been approved by the European Commission.

HyQvia  is a product consisting of human normal immunoglobulin and recombinant human hyaluronidase, which can be administered subcutaneously as a replacement therapy.

It combines key benefits of intravenous and subcutaneous administration methods into a single product and has been shown in clinical trials to help prevent acute serious bacterial infections.

Baxter will introduce HyQvia in selected countries during 2013, with plans to expand the rollout to other EU countries next year.

Dr Ludwig Hantson, president of Baxter's bioscience business, said: "We look forward to introducing HyQvia in the coming weeks to support physicians and adult immunodeficient patients in Europe."

Last month, the company reported its financial results for the first quarter of 2013, during which it achieved a two percent year-on-year increase in global sales, allowing it to confirm its previous guidance for the full 12-month period.